General Information:

Id: 2,138 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mammalia
article
Reference: Nofer JR et al.(2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113: 569-581 [PMID: 14966566]

Interaction Information:

Comment The three lysophospholipids present in HDL: sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF) elevated intracellular Ca2+ concentration and activated Akt and eNOS, which resulted in NO release and vasodilation.
Formal Description
Interaction-ID: 17657

drug/chemical compound

Sphingosylphosphorylcholine

increases_quantity of

drug/chemical compound

Ca2+

Comment The three lysophospholipids present in HDL: sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF) elevated intracellular Ca2+ concentration and activated Akt and eNOS, which resulted in NO release and vasodilation.
Formal Description
Interaction-ID: 17659

drug/chemical compound

Sphingosine 1-phosphate

increases_quantity of

drug/chemical compound

Ca2+

Comment The three lysophospholipids present in HDL: sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF) elevated intracellular Ca2+ concentration and activated Akt and eNOS, which resulted in NO release and vasodilation.
Formal Description
Interaction-ID: 17660

drug/chemical compound

Lysosulfatide

increases_quantity of

drug/chemical compound

Ca2+

Comment In endothelial cells from S1P3-deficient mice, Akt phosphorylation and Ca2+ increase in response to HDL and lysophospholipids were severely reduced.
Formal Description
Interaction-ID: 17676

gene/protein

S1PR3

affects_quantity of

drug/chemical compound

Ca2+

if induced by HDL, SPC, S1P, or LSF